Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Immunol ; 176(4): 2581-9, 2006 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-16456020

RESUMO

Expression of CXCR3-targeting chemokines have been demonstrated in several diseases, suggesting a critical role for CXCR3 in recruiting activated T cells to sites of immune-mediated inflammation. Sjögren's syndrome (SS) is an autoimmune disease characterized by a mononuclear cell infiltrate of activated T cells around the duct in the salivary gland. Analysis of minor salivary gland biopsy specimens from 20 healthy subjects and 18 patients with primary SS demonstrated that CXCR3, in particular, the B form of this receptor, is constitutively expressed by human salivary gland epithelial cells. Salivary gland epithelial cell cultures demonstrated that CXCR3 participate in removing relevant amount of agonists from the supernatant of exposed cells without mediating calcium flux or chemotaxis while retaining the ability to undergo internalization. Although in normal salivary gland epithelial cells, CXCR3 behaves as a chemokine-scavenging receptor, its role in SS cells is functionally impaired. The impairment of this scavenging function might favor chemotaxis, leading to heightened immigration of CXCR3-positive T lymphocytes. These findings suggest that epithelial CXCR3 may be involved in postsecretion regulation of chemokine bioavailability. They also support a critical role for CXCR3 in the pathogenesis of SS and identify its agonists as potential therapeutic targets.


Assuntos
Quimiocinas/metabolismo , Células Epiteliais/metabolismo , Receptores de Quimiocinas/metabolismo , Glândulas Salivares/metabolismo , Síndrome de Sjogren/metabolismo , Adulto , Idoso , Disponibilidade Biológica , Células Cultivadas , Quimiocina CXCL10 , Quimiocinas CXC/metabolismo , Quimiotaxia , Células Epiteliais/citologia , Feminino , Humanos , Ligantes , Pessoa de Meia-Idade , Receptores CXCR3 , Receptores de Quimiocinas/agonistas , Glândulas Salivares/citologia , Glândulas Salivares/imunologia , Síndrome de Sjogren/imunologia
2.
J Clin Invest ; 115(2): 369-78, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15650771

RESUMO

B cell chronic lymphocytic leukemia (B-CLL) is a neoplastic disorder characterized by accumulation of B lymphocytes due to uncontrolled growth and resistance to apoptosis. Analysis of B cells freshly isolated from 40 patients with chronic lymphocytic leukemia demonstrated that the Src kinase Lyn, the switch molecule that couples the B cell receptor to downstream signaling, displays anomalous properties. Lyn is remarkably overexpressed at the protein level in leukemic cells as compared with normal B lymphocytes, with a substantial aliquot of the kinase anomalously present in the cytosol. Whereas in normal B lymphocytes Lyn activation is dependent on B cell-receptor stimulation, in resting malignant cells, the constitutive activity of the kinase accounts for high basal protein tyrosine phosphorylation and low responsiveness to IgM ligation. Addition of the Lyn inhibitors PP2 and SU6656 to leukemic cell cultures restores cell apoptosis, and treatment of malignant cells with drugs that induce cell apoptosis decreases both activity and amount of the tyrosine kinase. These findings suggest a direct correlation between high basal Lyn activity and defects in the induction of apoptosis in leukemic cells. They also support a critical role for Lyn in B-CLL pathogenesis and identify this tyrosine kinase as a potential therapeutic target.


Assuntos
Apoptose , Linfócitos B/metabolismo , Regulação Leucêmica da Expressão Gênica , Leucemia Linfocítica Crônica de Células B/metabolismo , Quinases da Família src/metabolismo , Linfócitos B/patologia , Regulação Leucêmica da Expressão Gênica/efeitos dos fármacos , Humanos , Imunoglobulina M/metabolismo , Indóis/farmacologia , Leucemia Linfocítica Crônica de Células B/patologia , Ativação Linfocitária/efeitos dos fármacos , Fosforilação/efeitos dos fármacos , Pirimidinas/farmacologia , Receptores de Antígenos de Linfócitos B/metabolismo , Transdução de Sinais/efeitos dos fármacos , Sulfonamidas/farmacologia , Células Tumorais Cultivadas , Quinases da Família src/antagonistas & inibidores
3.
FASEB J ; 17(13): 1886-8, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12897058

RESUMO

Aquaporin 2 (AQP2) phosphorylation at Ser-256 by protein kinase A (PKA) is a key signal for vasopressin-stimulated AQP2 insertion into the plasma membrane in renal cells. This study underscores the possible role of phosphorylation at Ser-256 in regulating AQP2 maturation. AQP2-transfected renal CD8 cells were incubated with brefeldin A (BFA) to accumulate newly synthesized AQP2 in the endoplasmic reticulum (ER), and AQP2 flow from ER to the vesicular compartment was analyzed after BFA washout. We found that a) in the ER, AQP2 is weakly phosphorylated; b) the amount of phosphorylated AQP2 (p-AQP2) at Ser-256 increased significantly during transit in the Golgi, even in the presence of the PKA inhibitor H89; and c) AQP2 transport from the Golgi to the vasopressin-regulated vesicular compartment occurred with a concomitant decrease in p-AQP2 at Ser-256. These results support the hypothesis that AQP2 transition in the Golgi apparatus is associated with a PKA-independent increase in AQP2 phosphorylation at Ser-256. Conversely, impaired constitutive phosphorylation in a Golgi-associated compartment occurring in cells expressing mutated S256A-AQP2 or E258K-AQP2 causes phosphorylation-defective AQP2 routing to lysosomes. This result might explain the molecular basis of the dominant form of nephrogenic diabetes insipidus caused by the mutation E258K-AQP2, in which the phenotype is caused by an impaired routing of AQP2.


Assuntos
Aquaporinas/metabolismo , Retículo Endoplasmático/metabolismo , Rim/metabolismo , Serina/metabolismo , Vesículas Transportadoras/metabolismo , Aquaporina 2 , Aquaporina 6 , Aquaporinas/química , Aquaporinas/genética , Linhagem Celular , Sequência Consenso , Diabetes Insípido Nefrogênico/genética , Complexo de Golgi/metabolismo , Humanos , Lisossomos/metabolismo , Modelos Biológicos , Mutação , Fosforilação , Proteínas Serina-Treonina Quinases/metabolismo , Transporte Proteico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA